Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of T2DM~* Treated with basal insulin for ≥ 6 months, with current dose stable for ≥ 6 weeks of ≥ 0.3 U/kg/day, with or without anti-hyperglycemic agents and in whom the Investigator feels advancement from basal to basal and bolus therapy is needed for the patient~* A1C 7.5-11.0% by central lab value at screening visit~* Already perform self-monitoring of blood glucose (SMBG) and willing to test blood glucose (BG) over the course of the study~* Body Mass Index of ≤ 40 kg/m2~Exclusion Criteria:~* Currently on or has been treated in the past year with insulin regimens that include bolus insulins except the need for insulins in the settings of acute illness or hospitalization~* History of type 1 diabetes mellitus (T1DM), or diabetic ketoacidosis (DKA), or secondary forms of diabetes such as cystic fibrosis~* Known hypersensitivity or allergy to insulin-glargine or its excipients or any other insulins~* Two or more severe hypoglycemic episodes within the prior year~* Hypoglycemia unawareness defined by history~* History of proliferative diabetic retinopathy~* Is currently unstable and/or has moderate-to-severe medical illness in the Investigator's judgment~* Uncontrolled hypertension (either treated or untreated) defined as a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 100 mmHg at screening~* History of recent major surgery within 6 months, or minor surgery within 3 months (such as appendectomy) prior to screening visit, or a planned surgery during the study period~* History of bariatric surgery~* Active chronic infections~* Women of child-bearing age who are pregnant, planning pregnancy, breast-feeding, or, if capable of pregnancy, are not practicing contraception if heterosexually active~* Known hypersensitivity to plastics/polymers/adhesives~* Known difficulties with adherence of adhesives, bandages, or dressings~* Participated in any research study within the past 30 days~* Currently participating in another investigational trial~* Use of short term or chronic systemic steroids within three months of entry into the study or likelihood that same might be required during the conduct of the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bolus Insulin Patch (Calibra Finesse) (Type: EXPERIMENTAL): Use of the wearable patch to deliver meal-related bolus insulin dose
- Insulin Pen (Novo-Nordisk FlexPen®) (Type: ACTIVE_COMPARATOR): Use of the pen device to deliver meal-related bolus insulin dose

Based on this trial design, predict the completion outcome and termination type (if applicable).